Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CF04
- Development stage
- Phase 2
- Lead developer
- Shanghai Puyou Biopharmaceutical
- Administration
- Ophthalmic
01
Overview
CF04 is a drug candidate initially developed by Shanghai Amphiprotech. It is currently in Phase 2 clinical development, with its primary therapeutic area being eye diseases. Specific details about its mechanism of action, molecular target, or modality have not been disclosed in the available sources. The drug appears to be an investigational pharmaceutical intended for ophthalmic indications[1].
02
Targets
FGFR1 (Fibroblast growth factor receptor 1)FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)FGFR4 (Fibroblast growth factor receptor 4)
Beyond the preview
Go deeper on CF04.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CF04.